BAKER BROS. ADVISORS LP
Institutional investor · Portfolio as of Q2 2026
Top Holdings84 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
INCYTE CORP | 30.8M | $3.5B | 17.5% | $85.05 | +50.64% | 30 qtrssince 2019-Q1 | Increased 62 |
BEIGENE LTD-ADR | 8.8M | $2.5B | 12.6% | $149.17 | +151.93% | 30 qtrssince 2019-Q1 | Increased 62 |
REVOLUTION MEDICINES INC | 11.4M | $2.1B | 10.7% | $56.61 | +280.60% | 22 qtrssince 2021-Q1 | Increased 73 |
MADRIGAL PHARMACEUTICALS INC | 2.1M | $1.2B | 5.8% | $166.64 | +223.38% | 30 qtrssince 2019-Q1 | Increased 62 |
ACADIA Pharmaceuticals Inc. | 42.9M | $1.1B | 5.4% | $27.49 | +7.60% | 30 qtrssince 2019-Q1 | Increased 62 |
KYMERA THERAPEUTICS INC | 8.7M | $992.7M | 5.0% | $40.75 | +208.13% | 24 qtrssince 2020-Q3 | Unchanged 0 |
INSMED INC | 8.8M | $937.8M | 4.7% | $87.39 | +42.34% | 30 qtrssince 2019-Q1 | Increased 69 |
CELCUITY INC | 7.9M | $828.2M | 4.2% | $25.54 | +272.24% | 12 qtrssince 2023-Q3 | Unchanged 0 |
Kodiak Sciences, Inc. | 19.9M | $776.1M | 3.9% | $33.79 | +16.38% | 30 qtrssince 2019-Q1 | Unchanged 0 |
RHYTHM PHARMACEUTICALS INC | 5.6M | $622.3M | 3.1% | $23.84 | +369.22% | 30 qtrssince 2019-Q1 | Unchanged 0 |
PRAXIS PRECISION MEDICINES I | 1.8M | $587M | 2.9% | $205.88 | +83.29% | 15 qtrssince 2022-Q4 | Unchanged 0 |
ALKERMES PLC | 10M | $524.6M | 2.6% | $26.97 | +82.27% | 9 qtrssince 2024-Q2 | Unchanged 0 |
SUMMIT THERAPEUTICS INC | 32.8M | $477.7M | 2.4% | $12.21 | +16.51% | 9 qtrssince 2024-Q2 | Decreased 0 |
GRAIL INC | 4M | $275M | 1.4% | $42.63 | +86.70% | 7 qtrssince 2024-Q4 | Unchanged 0 |
ABCELLERA BIOLOGICS INC | 33M | $259.1M | 1.3% | $16.77 | -27.02% | 23 qtrssince 2020-Q4 | Increased 53 |
IMMUNOVANT INC | 5.4M | $209.4M | 1.0% | $21.82 | +101.15% | 12 qtrssince 2023-Q3 | Decreased 0 |
IDEAYA BIOSCIENCES INC | 5M | $186.7M | 0.9% | $26.71 | +55.65% | 16 qtrssince 2022-Q3 | Increased 53 |
KINIKSA PHARMACEUTICALS INTL | 2.8M | $181.3M | 0.9% | $18.84 | +317.68% | 9 qtrssince 2024-Q2 | Increased 43 |
ROIVANT SCIENCES LTD | 4.7M | $166.9M | 0.8% | $13.62 | +169.79% | 15 qtrssince 2022-Q4 | Decreased 0 |
ARROWHEAD PHARMACEUTICALS IN | 2M | $162.4M | 0.8% | $33.91 | +162.84% | 5 qtrssince 2025-Q2 | Unchanged 0 |
BAKER BROS. ADVISORS LP manages $20B across 84 positions as of Q2 2026. Top holdings: INCY (17.5%), ONC (12.6%), RVMD (10.7%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 4/5.0.
Active quarter - 8 new positions, 8 exits, 16 increased. Top move: RVMD (INCREASED, conviction 73). Portfolio: $20.0B across 84 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR